← All indications
alpha 1-Antitrypsin Deficiency
Deficiency of the protease inhibitor ALPHA 1-ANTITRYPSIN that manifests primarily as PULMONARY EMPHYSEMA and LIVER CIRRHOSIS.
Drugs by status
Approved for this indication (1)
Phase 3 trials (1)
Phase 2 trials (18)
Phase 1 trials (13)
Other trials (3)
Organizations
Organization Involved with Phase 4 Indications (4)
Organization Involved with Phase 3 Indications (6)
Organization Involved with Phase 2 Indications (30)
- Vertex
- Adverum Biotechnologies, Inc.
- Octapharma
- Novartis
- Alnylam Pharmaceuticals
- Applied Genetic Technologies Corp
- Dicerna Pharmaceuticals, Inc.
- Mereo BioPharma
- National Institutes of Health (NIH)
- National Heart, Lung, and Blood Institute (NHLBI)
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Gerard Turino
- University of Pittsburgh
- Temple University
- University of Florida
- University of Miami
- University of Birmingham
- Columbia University
- Royal College of Surgeons, Ireland
- University of Cincinnati
- University of Copenhagen
- Medical University of South Carolina
- Icahn School of Medicine at Mount Sinai
- University of Massachusetts
- University of Alabama, Birmingham
- University of Texas, Tyler
- Washington University in St. Louis
- Alpha-1 Foundation
- Stony Wold-Herbert Fund, Inc.
- Arriva Pharmaceuticals, Inc.
Organization Involved with Phase 1 Indications (6)
Organization Involved with Other Experimental Indications (1)